Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Clinical trial NCT06815029 · RECRUITING

Trial details

NCT number: NCT06815029
Sponsor: City of Hope Medical Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Astrocytoma, IDH-Mutant, Grade 3 Recurrent Astrocytoma, IDH-Mutant, Grade 4 Recurrent Glioblastoma

Start date: 2025-06-17
Primary completion: 2030-10-11
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.